Elin H Thorarinsdottir1,2, Erna S Arnardottir1,2, Bryndis Benediktsdottir1,2, Christer Janson3, Isleifur Olafsson4, Allan I Pack5, Thorarinn Gislason6,7, Brendan T Keenan5. 1. Faculty of Medicine, The National University of Iceland, Reykjavík, Iceland. 2. Sleep Department (E7), Landspitali-The National University Hospital of Iceland, 108, Reykjavík, Iceland. 3. Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden. 4. Department of Clinical Biochemistry, Landspitali-The National University Hospital of Iceland, Reykjavík, Iceland. 5. Center for Sleep and Circadian Neurobiology and Division of Sleep Medicine/ Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 6. Faculty of Medicine, The National University of Iceland, Reykjavík, Iceland. thorarig@landspitali.is. 7. Sleep Department (E7), Landspitali-The National University Hospital of Iceland, 108, Reykjavík, Iceland. thorarig@landspitali.is.
Abstract
PURPOSE: Ferritin is an intracellular iron storage protein and a marker of inflammation. Studies have shown that subjects with obstructive sleep apnea (OSA) have higher levels of circulating pro-inflammatory cytokines, but little is known about the association between ferritin and OSA. The aims of the study were to evaluate serum ferritin (S-Ferritin) levels in OSA patients compared to levels in the general population and also examine the effect of obesity level and treatment with positive airway pressure (PAP) on S-Ferritin levels. METHODS: The OSA subjects (n = 796) were part of the Icelandic Sleep Apnea Cohort. The control subjects (n = 637) were randomly chosen Icelanders who participated in an epidemiological study. Propensity score (PS) methodologies were employed to minimize selection bias and strengthen causal inferences when comparing non-randomized groups. S-Ferritin levels were measured and all participants answered the same detailed questionnaire about sleep and health. Only OSA patients underwent a sleep study and were re-invited for a 2-year follow-up. RESULTS: S-Ferritin levels were significantly higher in OSA males than controls (213.3 vs. 197.3 μg/L, p = 0.007). However, after adjusting for confounders and using our PS methodology, no significant difference was found. S-Ferritin levels were not correlated with severity of OSA, obesity level, or clinical symptoms. Also, no significant change in S-Ferritin levels was found with 2 years of PAP treatment. CONCLUSIONS: S-Ferritin levels are comparable in OSA patients and controls and do not change consistently with obesity level or PAP treatment in our sample.
PURPOSE: Ferritin is an intracellular iron storage protein and a marker of inflammation. Studies have shown that subjects with obstructive sleep apnea (OSA) have higher levels of circulating pro-inflammatory cytokines, but little is known about the association between ferritin and OSA. The aims of the study were to evaluate serum ferritin (S-Ferritin) levels in OSApatients compared to levels in the general population and also examine the effect of obesity level and treatment with positive airway pressure (PAP) on S-Ferritin levels. METHODS: The OSA subjects (n = 796) were part of the Icelandic Sleep Apnea Cohort. The control subjects (n = 637) were randomly chosen Icelanders who participated in an epidemiological study. Propensity score (PS) methodologies were employed to minimize selection bias and strengthen causal inferences when comparing non-randomized groups. S-Ferritin levels were measured and all participants answered the same detailed questionnaire about sleep and health. Only OSApatients underwent a sleep study and were re-invited for a 2-year follow-up. RESULTS: S-Ferritin levels were significantly higher in OSA males than controls (213.3 vs. 197.3 μg/L, p = 0.007). However, after adjusting for confounders and using our PS methodology, no significant difference was found. S-Ferritin levels were not correlated with severity of OSA, obesity level, or clinical symptoms. Also, no significant change in S-Ferritin levels was found with 2 years of PAP treatment. CONCLUSIONS: S-Ferritin levels are comparable in OSApatients and controls and do not change consistently with obesity level or PAP treatment in our sample.
Authors: K Klipstein-Grobusch; J F Koster; D E Grobbee; J Lindemans; H Boeing; A Hofman; J C Witteman Journal: Am J Clin Nutr Date: 1999-06 Impact factor: 7.045
Authors: Mee Kyoung Kim; Ki Hyun Baek; Ki-Ho Song; Moo Il Kang; Ji Hoon Choi; Ji Cheol Bae; Cheol Young Park; Won Young Lee; Ki Won Oh Journal: Am J Hypertens Date: 2012-01-26 Impact factor: 2.689
Authors: Y Inoue; K Nakanishi; T Hiraga; M Okubo; T Murase; K Kosaka; S Miyakoshi; Y Mutoh; T Kobayashi Journal: Am J Med Sci Date: 1997-12 Impact factor: 2.378
Authors: Erla Björnsdóttir; Christer Janson; Jón F Sigurdsson; Philip Gehrman; Michael Perlis; Sigurdur Juliusson; Erna S Arnardottir; Samuel T Kuna; Allan I Pack; Thorarinn Gislason; Bryndis Benediktsdóttir Journal: Sleep Date: 2013-12-01 Impact factor: 5.849
Authors: N G Forouhi; A H Harding; M Allison; M S Sandhu; A Welch; R Luben; S Bingham; K T Khaw; N J Wareham Journal: Diabetologia Date: 2007-03-02 Impact factor: 10.122